Isoform switch of PKM2 in glioblastomas, overexpression of PKM2 in most tumor types via hypomethylation near the PKM gene promoter, and its prognostic value in head and neck cancer justify the development of PKM2 inhibitors as promising anti-cancer therapeutics. This evidence concerns the gene PKM and head and neck cancer.